CA3104504A1 - Traitement d'une maladie demyelinisante - Google Patents
Traitement d'une maladie demyelinisante Download PDFInfo
- Publication number
- CA3104504A1 CA3104504A1 CA3104504A CA3104504A CA3104504A1 CA 3104504 A1 CA3104504 A1 CA 3104504A1 CA 3104504 A CA3104504 A CA 3104504A CA 3104504 A CA3104504 A CA 3104504A CA 3104504 A1 CA3104504 A1 CA 3104504A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally
- optionally substituted
- mlkl
- purine
- dione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000016192 Demyelinating disease Diseases 0.000 title claims abstract description 35
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 claims abstract description 47
- 239000003112 inhibitor Substances 0.000 claims abstract description 28
- 206010012305 Demyelination Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 23
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 claims abstract description 15
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 60
- 150000003839 salts Chemical class 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- FNPPHVLYVGMZMZ-XBXARRHUSA-N necrosulfonamide Chemical compound COC1=NC=CN=C1NS(=O)(=O)C(C=C1)=CC=C1NC(=O)\C=C\C1=CC=C([N+]([O-])=O)S1 FNPPHVLYVGMZMZ-XBXARRHUSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- -1 3-Methoxy-2-pyrazinyl Chemical group 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 150000001356 alkyl thiols Chemical class 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 150000001504 aryl thiols Chemical class 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000004678 hydrides Chemical class 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical group NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- LITVSIIZRQQKPD-UHFFFAOYSA-N 1,3,7-trimethyl-8-methylsulfonylpurine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=C(S(C)(=O)=O)N2C LITVSIIZRQQKPD-UHFFFAOYSA-N 0.000 claims 2
- KXHISLFNISBCQV-UHFFFAOYSA-N 1,7-dimethyl-8-methylsulfonyl-3-prop-2-ynylpurine-2,6-dione Chemical compound CN1C(N(C=2N=C(N(C=2C1=O)C)S(=O)(=O)C)CC#C)=O KXHISLFNISBCQV-UHFFFAOYSA-N 0.000 claims 2
- PKTNSAUOEGPBML-UHFFFAOYSA-N 2-(1,7-dimethyl-8-methylsulfonyl-2,6-dioxopurin-3-yl)acetonitrile Chemical compound CN1C(N(C=2N=C(N(C=2C1=O)C)S(=O)(=O)C)CC#N)=O PKTNSAUOEGPBML-UHFFFAOYSA-N 0.000 claims 2
- HXXMAYJQHQBTAI-UHFFFAOYSA-N 3-[3-(3-chlorophenyl)prop-2-ynyl]-8-(cyclopropylmethylsulfonyl)-1,7-dimethylpurine-2,6-dione Chemical compound ClC=1C=C(C=CC=1)C#CCN1C(N(C(C=2N(C(=NC1=2)S(=O)(=O)CC1CC1)C)=O)C)=O HXXMAYJQHQBTAI-UHFFFAOYSA-N 0.000 claims 2
- ZTQLCNOQWGSELY-UHFFFAOYSA-N 3-[3-(3-hydroxyphenyl)prop-2-ynyl]-1,7-dimethyl-8-methylsulfonylpurine-2,6-dione Chemical compound OC=1C=C(C=CC=1)C#CCN1C(N(C(C=2N(C(=NC1=2)S(=O)(=O)C)C)=O)C)=O ZTQLCNOQWGSELY-UHFFFAOYSA-N 0.000 claims 2
- IONWGECJLWWQSG-UHFFFAOYSA-N 7-ethyl-1,3-dimethyl-8-methylsulfonylpurine-2,6-dione Chemical compound C(C)N1C(=NC=2N(C(N(C(C1=2)=O)C)=O)C)S(=O)(=O)C IONWGECJLWWQSG-UHFFFAOYSA-N 0.000 claims 2
- MQSGUWQGPIDQIN-UHFFFAOYSA-N 8-[(2,5-dimethoxyphenyl)methylsulfonyl]-1,3,7-trimethylpurine-2,6-dione Chemical compound COC1=C(CS(=O)(=O)C2=NC=3N(C(N(C(C=3N2C)=O)C)=O)C)C=C(C=C1)OC MQSGUWQGPIDQIN-UHFFFAOYSA-N 0.000 claims 2
- JZMIBUQLKYNKBV-UHFFFAOYSA-N 8-[(2,5-dimethoxyphenyl)methylsulfonyl]-1,7-dimethyl-3-[3-[2-(methylamino)pyridin-4-yl]prop-2-ynyl]purine-2,6-dione Chemical compound COC1=C(CS(=O)(=O)C2=NC=3N(C(N(C(C=3N2C)=O)C)=O)CC#CC2=CC(=NC=C2)NC)C=C(C=C1)OC JZMIBUQLKYNKBV-UHFFFAOYSA-N 0.000 claims 2
- SNRUTMWCDZHKKM-UHFFFAOYSA-N 1-[4-[methyl-[2-(3-sulfamoylanilino)pyrimidin-4-yl]amino]phenyl]-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound C=1C=NC(NC=2C=C(C=CC=2)S(N)(=O)=O)=NC=1N(C)C(C=C1)=CC=C1NC(=O)NC1=CC=C(OC(F)(F)F)C=C1 SNRUTMWCDZHKKM-UHFFFAOYSA-N 0.000 claims 1
- 101710083978 Mixed lineage kinase domain-like protein Proteins 0.000 description 33
- 108010083674 Myelin Proteins Proteins 0.000 description 22
- 102000006386 Myelin Proteins Human genes 0.000 description 22
- 210000005012 myelin Anatomy 0.000 description 22
- 230000015556 catabolic process Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 210000005036 nerve Anatomy 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 description 8
- 210000004116 schwann cell Anatomy 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000003007 myelin sheath Anatomy 0.000 description 7
- 101710156256 Myosin phosphatase Rho-interacting protein Proteins 0.000 description 6
- 208000028389 Nerve injury Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000008764 nerve damage Effects 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- 210000003050 axon Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 210000001428 peripheral nervous system Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 206010073696 Wallerian degeneration Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000009038 pharmacological inhibition Effects 0.000 description 3
- 230000008734 wallerian degeneration Effects 0.000 description 3
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- DSRJIHMZAQEUJV-UHFFFAOYSA-N Cuprizon Chemical compound C1CCCCC1=NNC(=O)C(=O)NN=C1CCCCC1 DSRJIHMZAQEUJV-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 description 2
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100237799 Mus musculus Mlkl gene Proteins 0.000 description 2
- 102000017099 Myelin-Associated Glycoprotein Human genes 0.000 description 2
- 108010013731 Myelin-Associated Glycoprotein Proteins 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 101150025038 RIPK3 gene Proteins 0.000 description 2
- 206010039670 Sciatic nerve injury Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000021597 necroptosis Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101100126625 Caenorhabditis elegans itr-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 1
- 206010010957 Copper deficiency Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010069382 Hereditary neuropathy with liability to pressure palsies Diseases 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001011662 Mus musculus Mixed lineage kinase domain-like protein Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005014 ectopic expression Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010072285 growth inhibitory proteins Proteins 0.000 description 1
- 102000053379 human MLKL Human genes 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des procédés d'inhibition ou de traitement de la démyélinisation (ou de traitement d'une maladie démyélinisante) comprenant l'administration à une personne qui en a besoin d'un inhibiteur de MLKL.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/091744 | 2018-06-19 | ||
| CN2018091744 | 2018-06-19 | ||
| PCT/CN2019/091478 WO2019242576A1 (fr) | 2018-06-19 | 2019-06-17 | Traitement d'une maladie démyélinisante |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3104504A1 true CA3104504A1 (fr) | 2019-12-26 |
Family
ID=68983504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3104504A Abandoned CA3104504A1 (fr) | 2018-06-19 | 2019-06-17 | Traitement d'une maladie demyelinisante |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA3104504A1 (fr) |
| WO (1) | WO2019242576A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024050825A1 (fr) * | 2022-09-09 | 2024-03-14 | National Institute Of Biological Sciences, Beijing | Composés utilisés en tant qu'inhibiteurs de mlkl |
-
2019
- 2019-06-17 WO PCT/CN2019/091478 patent/WO2019242576A1/fr active Application Filing
- 2019-06-17 CA CA3104504A patent/CA3104504A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019242576A1 (fr) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3128155C (fr) | Composes 3-carbonylamino-5-cyclopentyl-1h-pyrazole ayant une activite inhibitrice sur cdk2 | |
| KR102236605B1 (ko) | 피리도피리미딘온 cdk2/4/6 억제제 | |
| TWI822733B (zh) | 經取代之1,2-二氫-3H-吡唑并[3,4-d]嘧啶-3-酮 | |
| TWI731309B (zh) | 經取代吡化合物及其用途 | |
| AU2017274521B2 (en) | Method of treating liver fibrosis | |
| CA2559408C (fr) | Derives de carboline utiles dans l'inhibition de l'angiogenese | |
| TWI448464B (zh) | 聚（ａｄｐ－核糖）聚合酶（ｐａｒｐ）之二氫吡啶并酞嗪酮抑制劑 | |
| EP2730564B1 (fr) | Amines hétérocycles et utilisations associées | |
| CA2915561C (fr) | Nouveaux composes bicycliques substitues utilises comme inhibiteurs de bromodomaines | |
| CA3232906A1 (fr) | Inhibiteurs de pi3k-alpha et leurs procedes d'utilisation | |
| CA2961412C (fr) | Inhibition de canal ionique a potentiel de recepteur transitoire a1 | |
| CA3210224A1 (fr) | Inhibiteurs de cdk et leurs procedes d'utilisation | |
| JP2022546520A (ja) | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 | |
| EP3538513A1 (fr) | Composés antagonistes du récepteur de type toll et leurs méthodes d'utilisation | |
| CA2856103C (fr) | Morpholinylbenzotriazines destinees a etre utilisees en oncotherapie | |
| JP2020532585A (ja) | インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド | |
| CA2893597C (fr) | Lactames de diazole | |
| CA3120514A1 (fr) | Urees cycliques | |
| CA3178129A1 (fr) | Derives de pyridopyrimidinone et leur utilisation en tant que modulateurs du recepteur d'hydrocarbure aryle | |
| CA3110436A1 (fr) | Agoniste de proteine sting a haute activite | |
| CA3104504A1 (fr) | Traitement d'une maladie demyelinisante | |
| JP2008517065A (ja) | Ｂｒｃａ２−ｒａｄ５１相互作用の破壊のための組成物及び方法 | |
| EP2514753B1 (fr) | Dérivés de la 6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepine et compositions pharmaceutiques contenant ceux-ci en tant qu'agent hypnotique ou anesthésique et procédé pour leur préparation | |
| MC MK et al. | compositions containing the same as hypnotic or anesthetic agent and method for their preparation | |
| AU2012200474A1 (en) | Carboline derivatives useful in the inhibition of angiogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201218 |
|
| FZDE | Discontinued |
Effective date: 20221219 |
|
| FZDE | Discontinued |
Effective date: 20221219 |